EX-99.1 2 exhibit99q22019.htm EXHIBIT 99.1 Exhibit
EXHIBIT 99.1



zoetisca04a01a01a01a01a15.jpg



Zoetis Announces Second Quarter 2019 Results

•
Reports Revenue of $1.5 Billion, Growing 9%, and Net Income of $371 Million, or $0.77 per Diluted Share, Decreasing 3%, on a Reported Basis for Second Quarter 2019
•
Reports Adjusted Net Income of $436 Million, or Adjusted Diluted EPS of $0.90, for Second Quarter 2019
•
Delivers 14% Operational Growth in Revenue and 17% Operational Growth in Adjusted Net Income for Second Quarter 2019
•
Raises Full Year 2019 Revenue Guidance to $6.175 - $6.275 Billion and Diluted EPS of $2.93 - $3.04 on a Reported Basis, or $3.53 - $3.60 on an Adjusted Basis


PARSIPPANY, N.J. - Aug. 6, 2019 - Zoetis Inc. (NYSE: ZTS) today reported its financial results for the second quarter of 2019 and raised its guidance for full year 2019.

The company reported revenue of $1.5 billion for the second quarter of 2019, an increase of 9% compared with the second quarter of 2018. Net income for the second quarter of 2019 was $371 million, or $0.77 per diluted share, a decrease of 3%, on a reported basis.

Adjusted net income1 for the second quarter of 2019 was $436 million, or $0.90 per diluted share, an increase of 16% and 17%, respectively, on a reported basis. Adjusted net income for the second quarter of 2019 excludes the net impact of $65 million for purchase accounting adjustments, acquisition-related costs and certain significant items.

On an operational2 basis, revenue for the second quarter of 2019 increased 14%, excluding the impact of foreign currency. Adjusted net income for the second quarter of 2019 increased 17% operationally, excluding the impact of foreign currency.

EXECUTIVE COMMENTARY
“We continued our strong performance through the first half of the year, with 14% operational revenue growth in the second quarter,” said Juan Ramόn Alaix, Chief Executive Officer at Zoetis. “Our companion animal portfolio is continuing its positive momentum, with 22% operational revenue

1 |

growth, based on diagnostic sales from the Abaxis acquisition, strong sales of our key dermatology products, and parasiticides. Livestock product sales returned to growth in the second quarter at 3% operationally, with increases across all species.”

“We remain confident that our latest innovations combined with our core business will spur future growth and profitability, and I am pleased to report that we have increased our full-year guidance for 2019,” said Alaix.

QUARTERLY HIGHLIGHTS
Zoetis organizes and manages its commercial operations across two segments: United States (U.S.) and International. Within these segments, the company delivers a diverse portfolio of products for livestock and companion animals, tailored to local trends and customer needs. In the second quarter of 2019:

•
Revenue in the U.S. segment was $780 million, an increase of 15% compared with the second quarter of 2018. Sales of companion animal products grew 23% driven primarily by the acquisition of Abaxis, key dermatology products, and a number of our in-line products including Simparica®, Clavamox®, Cerenia® and ProHeart® 6. Sales of livestock products grew 3% in the quarter, driven primarily by poultry products from increased sales of alternatives to antibiotics in medicated feed additives. Promotional activity resulted in modest growth in our swine portfolio, which was offset by a modest decline in cattle products due to continued weakness in both the dairy and beef sectors.

•
Revenue in the International segment was $742 million, an increase of 2% on a reported basis and an increase of 10% operationally, compared with the second quarter of 2018. Sales of companion animal products grew 12% on a reported basis and 21% on an operational basis. Growth resulted primarily from increased sales across our key dermatology portfolio, parasiticides, including Simparica and Stronghold® Plus, and the acquisition of Abaxis. Sales of livestock products declined 4% on a reported basis, but increased 4% operationally. Growth in our poultry portfolio was driven by increased sales of vaccines and medicated feed additives. Growth in cattle product sales was the result of a favorable comparison to the prior year which was negatively impacted by a national trucking strike in Brazil. Sales of swine products were flat compared to the prior year, with growth in vaccines, including new products, offset by the ongoing impact of African Swine Fever in China.    

INVESTMENTS IN GROWTH
Zoetis diversifies and grows its business through the introduction of new products, lifecycle innovations, business development initiatives, and entries into new markets and technologies. The company is increasingly focused on developing integrated solutions for veterinarians and farmers that span the continuum of animal healthcare - helping to predict, prevent, detect and treat diseases.

Zoetis is strengthening its parasiticide portfolio for companion animals with new internal innovations. In July, the company received a positive opinion from the European Medicines Agency's Committee

2 |

for Medicinal Products for Veterinary Use (CVMP) for our three-way combination parasiticide for dogs, and looks forward to the final decision from the European Commission later this year. Regulatory reviews are also underway in the U.S., Canada, Australia, Brazil and Japan, with further submissions expected in China and Mexico this year. If approved, Zoetis anticipates this product coming to market in Europe and the U.S. in 2020. The company also recently gained U.S. Food and Drug Administration (FDA) approval of ProHeart 12 (moxidectin), the industry’s only once-yearly injection to prevent heartworm disease in dogs 12 months of age and older.

In the second quarter, Zoetis expanded its Fostera® swine vaccine franchise with approvals of different formulations in new geographies. Fostera Gold PCV MH was approved in Brazil. This vaccine, currently commercially available in the U.S., Canada and several other markets, provides livestock farmers with greater options and flexibility in protecting pigs from porcine circovirus (PCV2) and Mycoplasma hyopneumoniae (M. hyo). Fostera PCV, a single-dose vaccine that aids in the prevention of PCV2, was also approved in China.

In addition to new product approvals and lifecycle innovations, Zoetis continues to support future growth through business development activities. The company recently announced plans to acquire Platinum Performance, a privately held, nutrition-focused animal heath company. Platinum’s premium nutritional product formulas and unique approach to the field of scientific wellness for horses, dogs and cats will further strengthen and diversify Zoetis’ portfolio in the equine and petcare markets. The acquisition is expected to be completed in the third quarter of 2019 after customary closing conditions are met. The company also signed an agreement with Colorado State University (CSU) to establish a research lab at CSU that will explore the livestock immune system and target new immunotherapies that could serve as alternatives to antibiotics in food production animals.


FINANCIAL GUIDANCE

Zoetis is raising its full year 2019 guidance, which includes:

•
Revenue between $6.175 billion and $6.275 billion
•
Reported diluted EPS between $2.93 and $3.04
•
Adjusted diluted EPS between $3.53 and $3.60
This increased guidance reflects the ongoing strength and performance of our business, as well as foreign exchange rates as of late July. Additional details on guidance are included in the financial tables and will be discussed on the company's conference call this morning.




3 |

WEBCAST & CONFERENCE CALL DETAILS
Zoetis will host a webcast and conference call at 8:30 a.m. (ET) today, during which company executives will review second quarter 2019 results, discuss financial guidance and respond to questions from financial analysts. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. A replay of the webcast will be archived and made available on Aug. 6, 2019.



About Zoetis
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2018, the company generated annual revenue of $5.8 billion with approximately 10,000 employees. For more information, visit www.zoetis.com.
1 Adjusted net income and its components and adjusted diluted earnings per share (non-GAAP financial measures) are defined as reported net income attributable to Zoetis and reported diluted earnings per share, excluding purchase accounting adjustments, acquisition-related costs and certain significant items.

2 Operational revenue growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange.


DISCLOSURE NOTICES

Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, future guidance, future operating models, expectations regarding products, product approvals or products under development, expected timing of product launches, expectations regarding the performance of acquired companies and our ability to integrate new businesses, expectations regarding the financial impact of acquisitions, future use of cash and dividend payments, tax rate and tax regimes, changes in the tax regimes and laws in other jurisdictions, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, including in the sections

4 |

thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.
 
Use of Non-GAAP Financial Measures: We use non-GAAP financial measures, such as adjusted net income, adjusted diluted earnings per share and operational results (which exclude the impact of foreign exchange), to assess and analyze our results and trends and to make financial and operational decisions. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this press release should not be considered alternatives to measurements required by GAAP, such as net income, operating income, and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliation of non-GAAP financial measures and GAAP financial measures are included in the tables accompanying this press release and are posted on our website at www.zoetis.com.

Internet Posting of Information: We routinely post information that may be important to investors in the 'Investors' section of our website at www.zoetis.com, on our Facebook page at http://www.facebook.com/zoetis and on Twitter @zoetis. We encourage investors and potential investors to consult our website regularly and to follow us on Facebook and Twitter for important information about us.

###

Media Contacts:
 
Investor Contacts:
Bill Price
 
Steve Frank
1-973-443-2742 (o)
 
1-973-822-7141 (o)
william.price@zoetis.com
 
steve.frank@zoetis.com
 
 
 
Kristen Seely
 
Marissa Patel
1-973-443-2777 (o)
 
1-973-443-2996 (o)
kristen.seely@zoetis.com
 
marissa.patel@zoetis.com

5 |

ZOETIS INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME(a) 
(UNAUDITED)
(millions of dollars, except per share data)

 
Quarter Ended
 
 
 
Six Months Ended
 
 
June 30,
 
 
 
June 30,
 
 
2019
 
2018
 
% Change
 
2019
 
2018
 
% Change
Revenue
$
1,547

 
$
1,415

 
9
 
$
3,002

 
$
2,781

 
8
Costs and expenses:
 
 
 
 
 
 
 
 
 
 
 
Cost of sales
465

 
447

 
4
 
983

 
894

 
10
Selling, general and administrative expenses
406

 
359

 
13
 
775

 
697

 
11
Research and development expenses
111

 
102

 
9
 
213

 
199

 
7
Amortization of intangible assets
39

 
23

 
70
 
77

 
46

 
67
Restructuring charges and certain acquisition-related costs
22

 
5

 
*
 
27

 
7

 
*
Interest expense
55

 
46

 
20
 
111

 
93

 
19
Other (income)/deductions–net
(6
)
 
(4
)
 
50
 
(20
)
 
(9
)
 
*
Income before provision for taxes on income
455

 
437

 
4
 
836

 
854

 
(2)
Provision for taxes on income
84

 
55

 
53
 
153

 
122

 
25
Net income before allocation to noncontrolling interests
371

 
382

 
(3)
 
683

 
732

 
(7)
Less: Net loss attributable to noncontrolling interests
—

 
(2
)
 
(100)
 
—

 
(4
)
 
(100)
Net income attributable to Zoetis
$
371

 
$
384

 
(3)
 
$
683

 
$
736

 
(7)
 
 
 
 
 
 
 
 
 
 
 
 
Earnings per share—basic
$
0.77

 
$
0.79

 
(3)
 
$
1.43

 
$
1.52

 
(6)
 
 
 
 
 
 
 
 
 
 
 
 
Earnings per share—diluted
$
0.77

 
$
0.79

 
(3)
 
$
1.41

 
$
1.51

 
(7)
 
 
 
 
 
 
 
 
 
 
 
 
Weighted-average shares used to calculate earnings per share
 
 
 
 
 
 
 
 
 
 
 
Basic
478.8

 
483.8

 
 
 
479.2

 
484.8

 
 
Diluted
482.3

 
487.5

 
 
 
482.7

 
488.6

 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a)
The condensed consolidated statements of income present the quarter and six months ended June 30, 2019 and June 30, 2018. Subsidiaries operating outside the United States are included for the quarter and six months ended May 31, 2019 and May 31, 2018.
* Calculation not meaningful.
Certain amounts and percentages may reflect rounding adjustments.


6 |

ZOETIS INC.
RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS
(UNAUDITED)
(millions of dollars, except per share data)

 
Quarter Ended June 30, 2019
 
GAAP Reported(a)
 
Purchase Accounting Adjustments
 
Acquisition- Related Costs(1)
 
Certain Significant Items(2)
 
Non-GAAP Adjusted(b)
Cost of sales
$
465

 
$
(5
)
 
$
—

 
$
(3
)
 
$
457

Gross profit
1,082

 
5

 
—

 
3

 
1,090

Selling, general and administrative expenses
406

 
(18
)
 
—

 
—

 
388

Research and development expenses
111

 
(1
)
 
—

 
—

 
110

Amortization of intangible assets
39

 
(34
)
 
—

 
—

 
5

Restructuring charges and certain acquisition-related costs
22

 
—

 
(22
)
 
—

 
—

Income before provision for taxes on income
455

 
58

 
22

 
3

 
538

Provision for taxes on income
84

 
13

 
4

 
1

 
102

Net income attributable to Zoetis
371

 
45

 
18

 
2

 
436

Earnings per common share attributable to Zoetis–diluted
0.77

 
0.09

 
0.04

 
—

 
0.90

 
 
 
 
 
 
 
 
 
 
 
Quarter Ended June 30, 2018
 
GAAP Reported(a)
 
Purchase Accounting Adjustments
 
Acquisition- Related Costs(1)
 
Certain Significant Items(2)
 
Non-GAAP Adjusted(b)
Cost of sales
$
447

 
$
(2
)
 
$
—

 
$
(2
)
 
$
443

Gross profit
968

 
2

 
—

 
2

 
972

Selling, general and administrative expenses
359

 
(2
)
 
—

 
—

 
357

Amortization of intangible assets
23

 
(19
)
 
—

 
—

 
4

Restructuring charges and certain acquisition-related costs
5

 
—

 
—

 
(5
)
 
—

Income before provision for taxes on income
437

 
23

 
—

 
7

 
467

Provision for taxes on income
55

 
4

 
—

 
35

 
94

Net income attributable to Zoetis
384

 
19

 
—

 
(28
)
 
375

Earnings per common share attributable to Zoetis–diluted
0.79

 
0.04

 
—

 
(0.06
)
 
0.77

(a)
The condensed consolidated statements of income present the quarter and six months ended June 30, 2019 and June 30, 2018. Subsidiaries operating outside the United States are included for the quarter and six months ended May 31, 2019 and May 31, 2018.
(b)
Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.
See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2).
Certain amounts may reflect rounding adjustments.


7 |

ZOETIS INC.
RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS - Continued
(UNAUDITED)
(millions of dollars, except per share data)

 
Six Months Ended June 30, 2019
 
GAAP Reported(a)
 
Purchase Accounting Adjustments
 
Acquisition- Related Costs(1)
 
Certain Significant Items(2)
 
Non-GAAP Adjusted(b)
Cost of sales
$
983

 
$
(19
)
 
$
—

 
$
(73
)
 
$
891

Gross profit
2,019

 
19

 
—

 
73

 
2,111

Selling, general and administrative expenses
775

 
(36
)
 
—

 
—

 
739

Research and development expenses
213

 
(1
)
 
—

 
—

 
212

Amortization of intangible assets
77

 
(68
)
 
—

 
—

 
9

Restructuring charges and certain acquisition-related costs
27

 
—

 
(27
)
 
—

 
—

Income before provision for taxes on income
836

 
124

 
27

 
73

 
1,060

Provision for taxes on income
153

 
33

 
5

 
9

 
200

Net income attributable to Zoetis
683

 
91

 
22

 
64

 
860

Earnings per common share attributable to Zoetis–diluted
1.41

 
0.19

 
0.05

 
0.13

 
1.78

 
 
 
 
 
 
 
 
 
 
 
Six Months Ended June 30, 2018
 
GAAP Reported(a)
 
Purchase Accounting Adjustments
 
Acquisition- Related Costs(1)
 
Certain Significant Items(2)
 
Non-GAAP Adjusted(b)
Cost of sales
$
894

 
$
(4
)
 
$
—

 
$
(3
)
 
$
887

Gross profit
1,887

 
4

 
—

 
3

 
1,894

Selling, general and administrative expenses
697

 
(3
)
 
—

 
(1
)
 
693

Research and development expenses
199

 
(1
)
 
—

 
—

 
198

Amortization of intangible assets
46

 
(38
)
 
—

 
—

 
8

Restructuring charges and certain acquisition-related costs
7

 
—

 
(1
)
 
(6
)
 
—

Income before provision for taxes on income
854

 
46

 
1

 
10

 
911

Provision for taxes on income
122

 
15

 
—

 
38

 
175

Net income attributable to Zoetis
736

 
31

 
1

 
(28
)
 
740

Earnings per common share attributable to Zoetis–diluted
1.51

 
0.06

 
—

 
(0.06
)
 
1.51

(a)
The condensed consolidated statements of income present the quarter and six months ended June 30, 2019 and June 30, 2018. Subsidiaries operating outside the United States are included for the quarter and six months ended May 31, 2019 and May 31, 2018.
(b)
Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.
See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2).
Certain amounts may reflect rounding adjustments.

8 |

ZOETIS INC.
NOTES TO RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS
(UNAUDITED)
(millions of dollars)

(1)
Acquisition-related costs include the following:
 
Quarter Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2019
 
2018
 
2019
 
2018
Integration costs(a)
$
8

 
$
—

 
$
9

 
$
1

Restructuring charges(b)
14

 
—

 
18

 
—

Total acquisition-related costs—pre-tax
22

 
—

 
27

 
1

Income taxes(c)
4

 
—

 
5

 
—

Total acquisition-related costs—net of tax
$
18

 
$
—

 
$
22

 
$
1

(a)
Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and the integration of systems and processes. Included in Restructuring charges and certain acquisition-related costs.
(b)
Represents employee termination costs, included in Restructuring charges and certain acquisition-related costs.
(c)
Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate.
Certain amounts may reflect rounding adjustments.
(2)
Certain significant items include the following:
 
Quarter Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2019
 
2018
 
2019
 
2018
Operational efficiency initiative(a)
$
—

 
$
1

 
$
—

 
$
1

Supply network strategy(a)
3

 
3

 
5

 
5

Other restructuring charges and cost-reduction/productivity initiatives(b)
—

 
3

 
—

 
3

Other(c)
—

 
—

 
68

 
1

Total certain significant items—pre-tax
3

 
7

 
73

 
10

Income taxes(d)
1

 
35

 
9

 
38

Total certain significant items—net of tax
$
2

 
$
(28
)
 
$
64

 
$
(28
)
(a)
Represents consulting fees and product transfer costs, included in Cost of sales, and employee termination costs and exit costs, included in Restructuring charges and certain acquisition-related costs, related to cost-reduction and productivity initiatives.
(b)
For the quarter and six months ended June 30, 2018, represents employee termination costs in Europe as a result of initiatives to better align our organizational structure, included in Restructuring charges and certain acquisition-related costs.
(c)
For the six months ended June 30, 2019, represents a change in estimate related to inventory costing, included in Cost of sales.
(d)
Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate. For the quarter and six months ended June 30, 2018, also includes a net tax benefit related to a measurement-period adjustment to the provisional one-time mandatory deemed repatriation tax on the company's undistributed non-U.S. earnings pursuant to the Tax Cuts and Jobs Act.
Certain amounts may reflect rounding adjustments.

9 |

ZOETIS INC.
ADJUSTED SELECTED COSTS, EXPENSES AND INCOME(a) 
(UNAUDITED)
(millions of dollars)

 
 
Quarter Ended
 
 
 
 
June 30,
 
% Change
 
 
2019

 
2018

 
Total
 
 
Foreign Exchange
 
Operational(b)
Adjusted cost of sales
 
$
457

 
$
443

 
3
%
 
 
(9
)%
 
12
%
as a percent of revenue
 
29.5
%
 
31.3
%
 
NA

 
 
NA

 
NA

Adjusted SG&A expenses
 
388

 
357

 
9
%
 
 
(3
)%
 
12
%
Adjusted R&D expenses
 
110

 
102

 
8
%
 
 
(2
)%
 
10
%
Adjusted net income attributable to Zoetis
 
436

 
375

 
16
%
 
 
(1
)%
 
17
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Six Months Ended
 
 
 
 
June 30,
 
% Change
 
 
2019
 
2018
 
Total
 
 
Foreign Exchange
 
Operational(b)
Adjusted cost of sales
 
$
891

 
$
887

 
—
%
 
 
(8
)%
 
8
%
as a percent of revenue
 
29.7
%
 
31.9
%
 
NA

 
 
NA

 
NA

Adjusted SG&A expenses
 
739

 
693

 
7
%
 
 
(3
)%
 
10
%
Adjusted R&D expenses
 
212

 
198

 
7
%
 
 
(2
)%
 
9
%
Adjusted net income attributable to Zoetis
 
860

 
740

 
16
%
 
 
(2
)%
 
18
%
 
 
 
 
 
 
 
 
 
 
 
 
(a)
Adjusted cost of sales, adjusted selling, general, and administrative (SG&A) expenses, adjusted research and development (R&D) expenses, and adjusted net income attributable to Zoetis (non-GAAP financial measures) are defined as the corresponding reported U.S. GAAP income statement line items excluding purchase accounting adjustments, acquisition-related costs, and certain significant items. These adjusted income statement line item measures are not, and should not be viewed as, substitutes for the corresponding U.S. GAAP line items. The corresponding GAAP line items and reconciliations of reported to adjusted information are provided in Condensed Consolidated Statements of Operations and Reconciliation of GAAP Reported to Non-GAAP Adjusted Information.
(b)
Operational growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange.


10 |

ZOETIS INC.
2019 GUIDANCE
Selected Line Items
(millions of dollars, except per share amounts)
Full Year 2019
Revenue
$6,175 to $6,275
   Operational growth(a)
8.5% to 10.0%
   Organic operational growth(b)
5.5% to 7.0%
Adjusted cost of sales as a percentage of revenue(c)
30% to 31%
Adjusted SG&A expenses(c)
$1,505 to $1,545
Adjusted R&D expenses(c)
$450 to $465
Adjusted interest expense and other (income)/deductions(c)
Approximately $190
Effective tax rate on adjusted income(c)
Approximately 20%
Adjusted diluted EPS(c)
$3.53 to $3.60
Adjusted net income(c)
$1,700 to $1,735
   Operational growth(a)(d)
9% to 12%
Certain significant items and acquisition-related costs(e)
$110 to $130
 
 
The guidance reflects foreign exchange rates as of late July 2019.
Reconciliations of 2019 reported guidance to 2019 adjusted guidance follows:
 
(millions of dollars, except per share amounts)
Reported
Certain significant items and acquisition-related costs(e)
Purchase accounting
Adjusted(c)
 
 
Cost of sales as a percentage of revenue
31.8% - 32.8%
~ (1.3%)
~ (0.5%)
30% - 31%
 
SG&A expenses
$1,580 to $1,620
 
($75)
$1,505 to $1,545
 
R&D expenses
$452 to $467
 
($2)
$450 to $465
 
Interest expense and other (income)/deductions
~ $190
 
 
~ $190
 
Effective tax rate
~ 20%
 
 
~ 20%
 
Diluted EPS
$2.93 to $3.04
$0.19 to $0.23
$0.37
$3.53 to $3.60
 
Net income attributable to Zoetis
$1,410 to $1,465
$90 to $110
~ $180
$1,700 to $1,735
(a)
Operational growth (a non-GAAP financial measure) excludes the impact of foreign exchange.
(b)
Organic operational growth (a non-GAAP financial measure) excludes the impact of the acquisition of Abaxis as well as foreign exchange.
(c)
Adjusted net income and its components and adjusted diluted EPS are defined as reported U.S. generally accepted accounting principles (GAAP) net income and its components and reported diluted EPS excluding purchase accounting adjustments, acquisition-related costs and certain significant items. Adjusted cost of sales, adjusted selling, general and administrative (SG&A) expenses, adjusted research and development (R&D) expenses, and adjusted interest expense and other (income)/deductions are income statement line items prepared on the same basis, and, therefore, components of the overall adjusted income measure. Despite the importance of these measures to management in goal setting and performance measurement, adjusted net income and its components and adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, adjusted net income and its components and adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Adjusted net income and its components and adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance. Adjusted net income and its components and adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS.
(d)
We do not provide a reconciliation of forward-looking non-GAAP adjusted net income operational growth to the most directly comparable GAAP reported financial measure because we are unable to calculate with reasonable certainty the foreign exchange impact of unusual gains and losses, acquisition-related expenses, potential future asset impairments and other certain significant items, without unreasonable effort. The foreign exchange impacts of these items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period.
(e)
Primarily includes certain nonrecurring costs related to the acquisition of Abaxis and other charges.

11 |

ZOETIS INC.
CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES
(UNAUDITED)
(millions of dollars)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quarter Ended
 
 
 
 
June 30,
 
% Change
 
 
2019
 
2018
 
Total
 
 
Foreign Exchange
 
Operational(b)
Revenue:
 
 
 
 
 
 
 
 
 
 
 
Livestock
 
$
724

 
$
734

 
(1
)%
 
 
(4
)%
 
3
%
Companion Animal
 
798

 
671

 
19
 %
 
 
(3
)%
 
22
%
Contract Manufacturing & Human Health Diagnostics
 
25

 
10

 
*

 
 
*

 
*

Total Revenue
 
$
1,547

 
$
1,415

 
9
 %
 
 
(5
)%
 
14
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
U.S.
 
 
 
 
 
 
 
 
 
 
 
Livestock
 
$
280

 
$
271

 
3
 %
 
 
—
 %
 
3
%
Companion Animal
 
500

 
406

 
23
 %
 
 
—
 %
 
23
%
Total U.S. Revenue
 
$
780

 
$
677

 
15
 %
 
 
—
 %
 
15
%
 
 
 
 
 
 
 
 
 
 
 
 
International
 
 
 
 
 
 
 
 
 
 
 
Livestock
 
$
444

 
$
463

 
(4
)%
 
 
(8
)%
 
4
%
Companion Animal
 
298

 
265

 
12
 %
 
 
(9
)%
 
21
%
Total International Revenue
 
$
742

 
$
728

 
2
 %
 
 
(8
)%
 
10
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Livestock:
 
 
 
 
 
 
 
 
 
 
 
Cattle
 
$
379

 
$
396

 
(4
)%
 
 
(5
)%
 
1
%
Swine
 
158

 
165

 
(4
)%
 
 
(5
)%
 
1
%
Poultry
 
143

 
129

 
11
 %
 
 
(4
)%
 
15
%
Fish
 
25

 
24

 
4
 %
 
 
(2
)%
 
6
%
Other
 
19

 
20

 
(5
)%
 
 
(5
)%
 
—
%
Total Livestock Revenue
 
$
724

 
$
734

 
(1
)%
 
 
(4
)%
 
3
%
 
 
 
 
 
 
 
 
 
 
 
 
Companion Animal:
 
 
 
 
 
 
 
 
 
 
 
Dogs and Cats
 
$
754

 
$
630

 
20
 %
 
 
(3
)%
 
23
%
Horses
 
44

 
41

 
7
 %
 
 
(3
)%
 
10
%
Total Companion Animal Revenue
 
$
798

 
$
671

 
19
 %
 
 
(3
)%
 
22
%
 
 
 
 
 
 
 
 
 
 
 
 
(a)
For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.
(b)
Operational revenue growth (a non-GAAP financial measure) is defined as revenue growth excluding the impact of foreign exchange.
*Calculation not meaningful.
Certain amounts and percentages may reflect rounding adjustments.









12 |



ZOETIS INC.
CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES - Continued
(UNAUDITED)
(millions of dollars)

 
 
Six Months Ended
 
 
 
 
June 30,
 
% Change
 
 
2019
 
2018
 
Total
 
 
Foreign Exchange
 
Operational(b)
Revenue:
 
 
 
 
 
 
 
 
 
 
 
Livestock
 
$
1,431

 
$
1,504

 
(5
)%
 
 
(5
)%
 
—
 %
Companion Animal
 
1,527

 
1,261

 
21
 %
 
 
(4
)%
 
25
 %
Contract Manufacturing & Human Health Diagnostics
 
44

 
16

 
*

 
 
*

 
*

Total Revenue
 
$
3,002

 
$
2,781

 
8
 %
 
 
(4
)%
 
12
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
U.S.
 
 
 
 
 
 
 
 
 
 
 
Livestock
 
$
553

 
$
563

 
(2
)%
 
 
—
 %
 
(2
)%
Companion Animal
 
945

 
748

 
26
 %
 
 
—
 %
 
26
 %
Total U.S. Revenue
 
$
1,498

 
$
1,311

 
14
 %
 
 
—
 %
 
14
 %
 
 
 
 
 
 
 
 
 
 
 
 
International
 
 
 
 
 
 
 
 
 
 
 
Livestock
 
$
878

 
$
941

 
(7
)%
 
 
(8
)%
 
1
 %
Companion Animal
 
582

 
513

 
13
 %
 
 
(9
)%
 
22
 %
Total International Revenue
 
$
1,460

 
$
1,454

 
—
 %
 
 
(8
)%
 
8
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Livestock:
 
 
 
 
 
 
 
 
 
 
 
Cattle
 
$
759

 
$
812

 
(7
)%
 
 
(6
)%
 
(1
)%
Swine
 
307

 
340

 
(10
)%
 
 
(5
)%
 
(5
)%
Poultry
 
282

 
265

 
6
 %
 
 
(5
)%
 
11
 %
Fish
 
48

 
46

 
4
 %
 
 
(3
)%
 
7
 %
Other
 
35

 
41

 
(15
)%
 
 
(6
)%
 
(9
)%
Total Livestock Revenue
 
$
1,431

 
$
1,504

 
(5
)%
 
 
(5
)%
 
—
 %
 
 
 
 
 
 
 
 
 
 
 
 
Companion Animal:
 
 
 
 
 
 
 
 
 
 
 
Dogs and Cats
 
$
1,442

 
$
1,179

 
22
 %
 
 
(4
)%
 
26
 %
Horses
 
85

 
82

 
4
 %
 
 
(4
)%
 
8
 %
Total Companion Animal Revenue
 
$
1,527

 
$
1,261

 
21
 %
 
 
(4
)%
 
25
 %
 
 
 
 
 
 
 
 
 
 
 
 
(a)
For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.
(b)
Operational revenue growth (a non-GAAP financial measure) is defined as revenue growth excluding the impact of foreign exchange.
*Calculation not meaningful.
Certain amounts and percentages may reflect rounding adjustments.




13 |

ZOETIS INC.
CONSOLIDATED REVENUE BY KEY INTERNATIONAL MARKETS
(UNAUDITED)
(millions of dollars)

 
 
Quarter Ended
 
 
 
 
June 30,
 
% Change
 
 
2019
 
2018
 
Total
 
 
Foreign Exchange
 
Operational(a)
Total International
 
$
741.9

 
$
727.9

 
2
 %
 
 
(8
)%
 
10
 %
Australia
 
48.8

 
50.9

 
(4
)%
 
 
(8
)%
 
4
 %
Brazil
 
74.2

 
68.3

 
9
 %
 
 
(15
)%
 
24
 %
Canada
 
53.7

 
55.6

 
(3
)%
 
 
(4
)%
 
1
 %
China
 
56.0

 
60.1

 
(7
)%
 
 
(6
)%
 
(1
)%
France
 
27.1

 
29.5

 
(8
)%
 
 
(8
)%
 
—
 %
Germany
 
39.1

 
38.4

 
2
 %
 
 
(8
)%
 
10
 %
Italy
 
27.6

 
26.1

 
6
 %
 
 
(8
)%
 
14
 %
Japan
 
41.1

 
39.1

 
5
 %
 
 
(3
)%
 
8
 %
Mexico
 
29.9

 
25.5

 
17
 %
 
 
(3
)%
 
20
 %
Spain
 
30.0

 
30.0

 
—
 %
 
 
(8
)%
 
8
 %
United Kingdom
 
42.3

 
36.1

 
17
 %
 
 
(7
)%
 
24
 %
Other developed markets
 
88.1

 
88.9

 
(1
)%
 
 
(6
)%
 
5
 %
Other emerging markets
 
184.0

 
179.4

 
3
 %
 
 
(10
)%
 
13
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Six Months Ended
 
 
 
 
June 30,
 
% Change
 
 
2019
 
2018
 
Total
 
 
Foreign Exchange
 
Operational(a)
Total International
 
$
1,459.9

 
$
1,453.8

 
—
 %
 
 
(8
)%
 
8
 %
Australia
 
96.8

 
98.5

 
(2
)%
 
 
(9
)%
 
7
 %
Brazil
 
134.3

 
137.9

 
(3
)%
 
 
(15
)%
 
12
 %
Canada
 
94.8

 
95.8

 
(1
)%
 
 
(5
)%
 
4
 %
China
 
115.5

 
124.0

 
(7
)%
 
 
(6
)%
 
(1
)%
France
 
59.4

 
62.7

 
(5
)%
 
 
(7
)%
 
2
 %
Germany
 
75.6

 
75.9

 
—
 %
 
 
(7
)%
 
7
 %
Italy
 
55.7

 
53.2

 
5
 %
 
 
(7
)%
 
12
 %
Japan
 
78.4

 
80.0

 
(2
)%
 
 
(1
)%
 
(1
)%
Mexico
 
58.0

 
49.9

 
16
 %
 
 
(3
)%
 
19
 %
Spain
 
57.1

 
55.3

 
3
 %
 
 
(7
)%
 
10
 %
United Kingdom
 
99.0

 
88.2

 
12
 %
 
 
(8
)%
 
20
 %
Other developed markets
 
171.9

 
168.2

 
2
 %
 
 
(6
)%
 
8
 %
Other emerging markets
 
363.4

 
364.2

 
—
 %
 
 
(11
)%
 
11
 %
(a)
Operational revenue growth (a non-GAAP financial measure) is defined as revenue growth excluding the impact of foreign exchange.
Certain amounts and percentages may reflect rounding adjustments.


14 |

ZOETIS INC.
SEGMENT(a) EARNINGS
(UNAUDITED)
(millions of dollars)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quarter Ended
 
 
 
 
June 30,
 
% Change
 
 
2019
 
2018
 
Total
 
 
Foreign Exchange
 
Operational(b)
U.S.:
 
 
 
 
 
 
 
 
 
 
 
Revenue
 
$
780

 
$
677

 
15
 %
 
 
—
 %
 
15
%
Cost of Sales
 
158

 
140

 
13
 %
 
 
—
 %
 
13
%
Gross Profit
 
622

 
537

 
16
 %
 
 
—
 %
 
16
%
    Gross Margin
 
79.7
%
 
79.3
%
 
 
 
 
 
 

Operating Expenses
 
127

 
116

 
9
 %
 
 
—
 %
 
9
%
Other (income)/deductions
 
—

 
—

 
—
 %
 
 
—
 %
 
—
%
U.S. Earnings
 
$
495

 
$
421

 
18
 %
 
 
—
 %
 
18
%
 
 
 
 
 
 
 
 
 
 
 
 
International:
 
 
 
 
 
 
 
 
 
 
 
Revenue
 
$
742

 
$
728

 
2
 %
 
 
(8
)%
 
10
%
Cost of Sales
 
218

 
229

 
(5
)%
 
 
(13
)%
 
8
%
Gross Profit
 
524

 
499

 
5
 %
 
 
(6
)%
 
11
%
    Gross Margin
 
70.6
%
 
68.5
%
 
 
 
 
 
 
 
Operating Expenses
 
146

 
147

 
(1
)%
 
 
(10
)%
 
9
%
Other (income)/deductions
 
—

 
2

 
*

 
 
*

 
*

International Earnings
 
$
378

 
$
350

 
8
 %
 
 
(4
)%
 
12
%
 
 
 
 
 
 
 
 
 
 
 
 
Total Reportable Segments
 
$
873

 
$
771

 
13
 %
 
 
(2
)%
 
15
%
 
 
 
 
 
 
 
 
 
 
 
 
Other business activities(c)
 
(79
)
 
(82
)
 
(4
)%
 
 
 
 
 
Reconciling Items:
 
 
 
 
 
 
 
 
 
 
 
Corporate(d)
 
(178
)
 
(139
)
 
28
 %
 
 
 
 
 
Purchase accounting adjustments(e)
 
(58
)
 
(23
)
 
*

 
 
 
 
 
Acquisition-related costs(f)
 
(22
)
 
—

 
*

 
 
 
 
 
Certain significant items(g)
 
(3
)
 
(7
)
 
(57
)%
 
 
 
 
 
Other unallocated(h)
 
(78
)
 
(83
)
 
(6
)%
 
 
 
 
 
Total Earnings(i)
 
$
455

 
$
437

 
4
 %
 
 
 
 
 
(a)
For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.
(b)
Operational growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange.
(c)
Other business activities reflect the research and development costs managed by our Research and Development organization as well as our contract manufacturing business and human health diagnostic business.
(d)
Corporate includes, among other things, administration expenses, interest expense, certain compensation costs, certain procurement costs, and other costs not charged to our operating segments.
(e)
Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments.
(f)
Acquisition-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs.
(g)
Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition, costs associated with the operational efficiency initiative and supply network strategy, and the impact of divestiture-related gains and losses.
(h)
Includes overhead expenses associated with our manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs.
(i)
Defined as income before provision for taxes on income.
* Calculation not meaningful.
Certain amounts and percentages may reflect rounding adjustments.

15 |

ZOETIS INC.
SEGMENT(a) EARNINGS - Continued
(UNAUDITED)
(millions of dollars)
 
 
Six Months Ended
 
 
 
 
June 30,
 
% Change
 
 
2019
 
2018
 
Total
 
 
Foreign Exchange
 
Operational(b)
U.S.:
 
 
 
 
 
 
 
 
 
 
 
Revenue
 
$
1,498

 
$
1,311

 
14
 %
 
 
—
 %
 
14
%
Cost of Sales
 
305

 
280

 
9
 %
 
 
—
 %
 
9
%
Gross Profit
 
1,193

 
1,031

 
16
 %
 
 
—
 %
 
16
%
    Gross Margin
 
79.6
%
 
78.6
%
 
 
 
 
 
 

Operating Expenses
 
237

 
212

 
12
 %
 
 
—
 %
 
12
%
Other (income)/deductions
 
—

 
—

 
—
 %
 
 
—
 %
 
—
%
U.S. Earnings
 
$
956

 
$
819

 
17
 %
 
 
—
 %
 
17
%
 
 
 
 
 
 
 
 
 
 
 
 
International:
 
 
 
 
 
 
 
 
 
 
 
Revenue
 
$
1,460

 
$
1,454

 
—
 %
 
 
(8
)%
 
8
%
Cost of Sales
 
428

 
463

 
(8
)%
 
 
(12
)%
 
4
%
Gross Profit
 
1,032

 
991

 
4
 %
 
 
(7
)%
 
11
%
    Gross Margin
 
70.7
%
 
68.2
%
 
 
 
 
 
 
 
Operating Expenses
 
278

 
280

 
(1
)%
 
 
(10
)%
 
9
%
Other (income)/deductions
 
—

 
3

 
*

 
 
*

 
*

International Earnings
 
$
754

 
$
708

 
6
 %
 
 
(5
)%
 
11
%
 
 
 
 
 
 
 
 
 
 
 
 
Total Reportable Segments
 
$
1,710

 
$
1,527

 
12
 %
 
 
(2
)%
 
14
%
 
 
 
 
 
 
 
 
 
 
 
 
Other business activities(c)
 
(159
)
 
(163
)
 
(2
)%
 
 
 
 
 
Reconciling Items:
 
 
 
 
 
 
 
 
 
 
 
Corporate(d)
 
(340
)
 
(292
)
 
16
 %
 
 
 
 
 
Purchase accounting adjustments(e)
 
(124
)
 
(46
)
 
*

 
 
 
 
 
Acquisition-related costs(f)
 
(27
)
 
(1
)
 
*

 
 
 
 
 
Certain significant items(g)
 
(73
)
 
(10
)
 
*

 
 
 
 
 
Other unallocated(h)
 
(151
)
 
(161
)
 
(6
)%
 
 
 
 
 
Total Earnings(i)
 
$
836

 
$
854

 
(2
)%
 
 
 
 
 
(a)
For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.
(b)
Operational growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange.
(c)
Other business activities reflect the research and development costs managed by our Research and Development organization as well as our contract manufacturing business and human health diagnostic business.
(d)
Corporate includes, among other things, administration expenses, interest expense, certain compensation costs, certain procurement costs, and other costs not charged to our operating segments.
(e)
Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments.
(f)
Acquisition-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs.
(g)
Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition, costs associated with the operational efficiency initiative and supply network strategy, and the impact of divestiture-related gains and losses.
(h)
Includes overhead expenses associated with our manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs.
(i)
Defined as income before provision for taxes on income.
* Calculation not meaningful.
Certain amounts and percentages may reflect rounding adjustments.

16 |